Read More Pharma Industry News EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race. byVenkateshNovember 12, 2025